CN114470302A - Hemostatic gel and preparation method thereof - Google Patents
Hemostatic gel and preparation method thereof Download PDFInfo
- Publication number
- CN114470302A CN114470302A CN202210061755.7A CN202210061755A CN114470302A CN 114470302 A CN114470302 A CN 114470302A CN 202210061755 A CN202210061755 A CN 202210061755A CN 114470302 A CN114470302 A CN 114470302A
- Authority
- CN
- China
- Prior art keywords
- hemostatic
- gel
- agent
- gelatin sponge
- mixing device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 238000001879 gelation Methods 0.000 title description 2
- 239000000499 gel Substances 0.000 claims abstract description 59
- 229940030225 antihemorrhagics Drugs 0.000 claims abstract description 40
- 108010010803 Gelatin Proteins 0.000 claims abstract description 37
- 239000008273 gelatin Substances 0.000 claims abstract description 37
- 229920000159 gelatin Polymers 0.000 claims abstract description 37
- 235000019322 gelatine Nutrition 0.000 claims abstract description 37
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 37
- 239000002874 hemostatic agent Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 230000003073 embolic effect Effects 0.000 claims abstract description 18
- 239000007787 solid Substances 0.000 claims abstract description 18
- 230000023597 hemostasis Effects 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 9
- 239000000084 colloidal system Substances 0.000 claims abstract description 8
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 108090000190 Thrombin Proteins 0.000 claims description 21
- 229960004072 thrombin Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 12
- 230000000025 haemostatic effect Effects 0.000 claims description 9
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 108010094028 Prothrombin Proteins 0.000 claims description 4
- 102100027378 Prothrombin Human genes 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 229940039716 prothrombin Drugs 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000013152 interventional procedure Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/104—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0036—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Abstract
The invention discloses a hemostatic gel and a preparation method thereof, wherein the preparation method comprises the following steps of obtaining a first preset amount of solid embolic agent, and crushing the solid embolic agent in a crushing device; obtaining a second preset quantity of the hemostatic agent, putting the hemostatic agent and the solid embolic agent into a mixing device, and starting the mixing device to mix, wherein the temperature of the mixing device is less than 30 ℃, the mixing time is not less than a second preset time, and the second preset quantity corresponds to the first preset quantity; and quantitatively packaging the mixed colloid to form the hemostatic gel. According to the technical scheme, the gelatin sponge is placed into a crushing device to be crushed to a specified particle size, the crushed gelatin sponge and the hemostatic agent in a certain proportion are mixed and subpackaged, the colloid amount after subpackaging is controlled, hemostatic gel is formed, and the hemostatic gel can play a role in physical hemostasis and chemical hemostasis simultaneously, so that when a doctor directly uses the hemostatic gel, the hemostatic time is saved, and the success rate of an operation is increased.
Description
Technical Field
The invention relates to the technical field of hemostatic gel, in particular to hemostatic gel.
Background
Bleeding from damaged large and medium arteries, large veins, must first be treated with surgery; cautiously used in bleeding caused by Disseminated Intravascular Coagulation (DIC); when the blood is lack of platelets or certain coagulation factors, the application is preferably based on platelet supplementation, coagulation factors or fresh blood infusion.
Disclosure of Invention
The invention mainly aims to provide a hemostatic gel, and aims to solve the problems that the existing hemostatic and gelatin sponge need to be used respectively for hemostasis, and the operation is inconvenient.
In order to achieve the above object, the present invention provides a hemostatic gel, and a method for preparing the hemostatic gel, which comprises the following steps:
obtaining a first preset amount of solid embolic agent, and putting the solid embolic agent into a crushing device for crushing, wherein the crushing time is not less than a first preset time, and the particle size of the crushed solid embolic agent is not more than 2000 mu m;
obtaining a second preset quantity of hemostatic agent, putting the hemostatic agent and the solid embolic agent into a mixing device, and starting the mixing device to mix, wherein the temperature of the mixing device is less than 30 ℃, the mixing time is not less than a second preset time, and the second preset quantity corresponds to the first preset quantity;
and quantitatively packaging the mixed colloid to form the hemostatic gel.
Preferably, the hemostatic agent comprises one or more of a coagulation factor, a prothrombin complex and thrombin, and the solid embolic agent comprises gelatin sponge or polyvinyl alcohol.
Preferably, the content of the gelatin sponge in the hemostatic gel formed is less than 300mg, the hemostatic agent comprises thrombin, and the content of thrombin is less than 3 ku.
Preferably, the content of the gelatin sponge in the formed hemostatic gel is 200mg, and the content of the thrombin is 2 ku.
Preferably, the content of the gelatin sponge in the formed hemostatic gel is 100mg, and the content of the thrombin is 1 ku.
Preferably, the step of quantitatively dispensing the mixed colloid comprises the following steps:
and storing the packed hemostatic gel in a dark place, wherein the storage temperature of the hemostatic gel is lower than 30 ℃.
Preferably, the steps of obtaining a second predetermined amount of hemostatic agent, placing the hemostatic agent and the gelatin sponge into a mixing device, and activating the mixing device to mix, comprise:
obtaining a second predetermined amount of hemostatic agent, placing the hemostatic agent and the gelatin sponge into a mixing device;
obtaining a third preset amount of dissolving agent corresponding to the first preset amount of gelatin sponge;
the mixing device is started to mix.
Preferably, the comminuting device and the mixing device are both sterile apparatuses.
A haemostatic gel formed by a method of preparing a haemostatic gel as described in any preceding claim, the haemostatic gel being for use in haemostasis.
Preferably, the haemostatic agent of the haemostatic gel is thrombin, and the haemostatic gel is used for haemostasis in interventional procedures.
According to the technical scheme, the gelatin sponge is placed into a crushing device to be crushed to a specified particle size, the crushed gelatin sponge and the hemostatic agent in a certain proportion are mixed and subpackaged, the colloid amount after subpackaging is controlled, hemostatic gel is formed, and the hemostatic gel can play a role in physical hemostasis and chemical hemostasis simultaneously, so that when a doctor directly uses the hemostatic gel, the hemostatic time is saved, and the success rate of an operation is increased.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the structures shown in the drawings without creative efforts.
FIG. 1 is a schematic flow chart of a method for preparing a hemostatic gel of the present invention.
The implementation, functional features and advantages of the objects of the present invention will be further explained with reference to the accompanying drawings.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
It should be noted that all the directional indicators (such as up, down, left, right, front, and rear … …) in the embodiment of the present invention are only used to explain the relative position relationship between the components, the movement situation, etc. in a specific posture (as shown in the drawing), and if the specific posture is changed, the directional indicator is changed accordingly.
In addition, the descriptions related to "first", "second", etc. in the present invention are only for descriptive purposes and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "a plurality" means at least two, e.g., two, three, etc., unless specifically limited otherwise.
In the present invention, unless otherwise expressly stated or limited, the terms "connected," "secured," and the like are to be construed broadly, and for example, "secured" may be a fixed connection, a removable connection, or an integral part; can be mechanically or electrically connected; they may be directly connected or indirectly connected through intervening media, or they may be connected internally or in any other suitable relationship, unless expressly stated otherwise. The specific meanings of the above terms in the present invention can be understood by those skilled in the art according to specific situations.
In addition, the technical solutions in the embodiments of the present invention may be combined with each other, but it must be based on the realization of those skilled in the art, and when the technical solutions are contradictory or cannot be realized, such a combination of technical solutions should not be considered to exist, and is not within the protection scope of the present invention.
Referring to fig. 1, the present invention provides a hemostatic gel and a method for preparing the hemostatic gel, comprising the following steps:
s100, obtaining a first preset amount of solid embolic agent, and putting the solid embolic agent into a crushing device for crushing, wherein the crushing time is not less than the first preset time, and the granularity of the crushed solid embolic agent is not more than 2000 mu m;
s200, obtaining a second preset quantity of hemostatic, putting the hemostatic and the solid embolic into a mixing device, and starting the mixing device to mix, wherein the temperature of the mixing device is less than 30 ℃, the mixing time is not less than a second preset time, and the second preset quantity corresponds to the first preset quantity;
and S300, quantitatively packaging the mixed colloid to form the hemostatic gel.
According to the technical scheme, the gelatin sponge is placed into a crushing device to be crushed to a specified particle size, the crushed gelatin sponge and the hemostatic agent in a certain proportion are mixed and subpackaged, the colloid amount after subpackaging is controlled, hemostatic gel is formed, and the hemostatic gel can play a role in physical hemostasis and chemical hemostasis simultaneously, so that when a doctor directly uses the hemostatic gel, the hemostatic time is saved, and the success rate of an operation is increased.
In another embodiment of the invention, the hemostatic agent comprises one or more of a coagulation factor, a prothrombin complex, and thrombin, and the solid embolic agent comprises gelatin sponge or polyvinyl alcohol.
The device comprises a gelatin sponge particle forming device, the gelatin sponge particle forming device can crush gelatin sponge into particles with the same size, the specification of the gelatin sponge is crushed into different specifications according to different using positions, the specification of the gelatin sponge comprises 150-350 micrometers, 350-560 micrometers, 560-710 micrometers, 710-1000 micrometers, 1000-1400 micrometers and 1400-2000 micrometers, the first preset time is 5-10 minutes, and the second preset time is 10-30 minutes.
In one embodiment of the invention, the gelatin sponge particles may be replaced by polyvinyl alcohol and iodized oil.
Specifically, the hemostatic agent may be selected from one or more of them depending on the site of use.
More specifically, in one embodiment of the invention, the hemostatic agent comprises a blood coagulation factor.
More specifically, in one embodiment of the invention, the prothrombin complex.
In yet another embodiment of the present invention, the hemostatic gel is formed with a content of less than 300mg of the gelatin sponge, the hemostatic agent comprises thrombin, and the thrombin is present in an amount of less than 3 ku.
In yet another embodiment of the present invention, the hemostatic gel is formed with a gelatin sponge content of 200mg and a thrombin content of 2 ku.
Specifically, hemostatic gels with different specifications and different proportions are arranged to adapt to different operations and bleeding modes.
In one embodiment of the present invention, the hemostatic gel is formed with a content of less than 200mg of the gelatin sponge, the hemostatic agent comprises thrombin, and the thrombin is present in an amount of less than 1 ku.
In one embodiment of the present invention, the hemostatic gel is formed with a content of less than 100mg of the gelatin sponge, the hemostatic agent comprises thrombin, and the thrombin is present in an amount of less than 2 ku.
In another embodiment of the present invention, the step S300 is followed by:
s400, storing the packed hemostatic gel in a dark place, wherein the storage temperature of the hemostatic gel is lower than 30 ℃.
In particular, the storage temperature and storage conditions are dependent on the hemostatic agent used.
In another embodiment of the present invention, the steps of obtaining a second predetermined amount of hemostatic agent, placing the hemostatic agent and the gelatin sponge into a mixing device, and activating the mixing device to mix, comprise:
s210, obtaining a second preset amount of hemostatic, and putting the hemostatic and the gelatin sponge into a mixing device;
s220, obtaining a third preset amount of mixture corresponding to the first preset amount of gelatin sponges,
and S230, starting a mixing device for mixing.
Specifically, a third predetermined amount of mixing agent corresponding to the first predetermined amount of gelatin sponge is obtained, and the gelatin sponge needs a certain amount of mixing agent to be mixed, wherein in one embodiment, the mixing agent is iodized oil.
In yet another embodiment of the present invention, the comminuting device and the mixing device are both sterile apparatuses.
In particular, the hemostatic gel is prevented from being contaminated, resulting in infection during surgery.
The invention also provides a hemostatic gel, which is prepared by the preparation method of any one of the hemostatic gels and is used for hemostasis.
In yet another embodiment of the invention, the hemostatic agent of the hemostatic gel is thrombin, the hemostatic gel is used for hemostasis in interventional procedures,
the above description is only a preferred embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications and equivalents of the present invention, which are made by the contents of the present specification and the accompanying drawings, or directly/indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. A preparation method of hemostatic gel is characterized by comprising the following steps:
obtaining a first preset amount of solid embolic agent, and putting the solid embolic agent into a crushing device for crushing, wherein the crushing time is not less than a first preset time, and the particle size of the crushed solid embolic agent is not more than 2000 mu m;
obtaining a second preset quantity of hemostatic, putting the hemostatic and the solid embolic into a mixing device, and starting the mixing device to mix, wherein the temperature of the mixing device is less than 30 ℃, the mixing time is not less than a second preset time, and the second preset quantity corresponds to the first preset quantity;
and quantitatively packaging the mixed colloid to form the hemostatic gel.
2. The method of claim 1, wherein the hemostatic agent comprises one or more of a clotting factor, a prothrombin complex, and thrombin, and the solid embolic agent comprises gelatin sponge or polyvinyl alcohol.
3. The method of claim 2, wherein the hemostatic gel is formed with a gelatin sponge content of less than 300mg, the hemostatic agent comprises thrombin, and the thrombin is present in an amount of less than 3 ku.
4. The method of claim 3, wherein the hemostatic gel is formed with a gelatin sponge content of 200mg and a thrombin content of 2 ku.
5. The method of claim 3, wherein the hemostatic gel is formed with a gelatin sponge content of 100mg and a thrombin content of 1 ku.
6. The method of claim 3, wherein the step of quantitatively dispensing the mixed gel comprises:
and storing the packed hemostatic gel in a dark place, wherein the storage temperature of the hemostatic gel is lower than 30 ℃.
7. The method of claim 2, wherein said steps of obtaining a second predetermined amount of hemostatic agent, placing said hemostatic agent and said gelatin sponge into a mixing device, and activating the mixing device to mix, comprise:
obtaining a second predetermined amount of hemostatic agent, placing the hemostatic agent and the gelatin sponge into a mixing device;
obtaining a third preset amount of dissolving agent corresponding to the first preset amount of gelatin sponge;
the mixing device is started to mix.
8. A method of preparing a haemostatic gel according to any of claims 1-7, wherein the comminuting means and the mixing means are sterile devices.
9. A haemostatic gel formed by a method of preparing a haemostatic gel according to any of claims 1-8, said haemostatic gel being for use in haemostasis.
10. The hemostatic gel according to claim 9, wherein said hemostatic agent of said hemostatic gel is thrombin, said hemostatic gel being used for hemostasis in interventional procedures.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210061755.7A CN114470302A (en) | 2022-01-19 | 2022-01-19 | Hemostatic gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210061755.7A CN114470302A (en) | 2022-01-19 | 2022-01-19 | Hemostatic gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114470302A true CN114470302A (en) | 2022-05-13 |
Family
ID=81472349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210061755.7A Pending CN114470302A (en) | 2022-01-19 | 2022-01-19 | Hemostatic gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470302A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0410383D0 (en) * | 2004-05-10 | 2004-06-16 | Johnson & Johnson Medical Ltd | Absorbable haemostatic materials |
| CN1615160A (en) * | 2001-12-21 | 2005-05-11 | 弗劳森公司 | A haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| US20110045034A1 (en) * | 2008-03-03 | 2011-02-24 | Israel Nur | Gelatin Sponge Comprising an Active Ingredient, Its Preparation and Use |
| CN103037847A (en) * | 2010-06-01 | 2013-04-10 | 巴克斯特国际公司 | Process for making dry and stable hemostatic compositions |
| CN108530671A (en) * | 2018-02-11 | 2018-09-14 | 广州迈普再生医学科技股份有限公司 | A kind of porous gelfoam and preparation method thereof |
| CN109821059A (en) * | 2019-04-16 | 2019-05-31 | 大连医科大学附属第一医院 | A kind of preparation method of absorbable fluid gelatin hemostatic material |
| US20190343981A1 (en) * | 2018-05-09 | 2019-11-14 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| CN113134113A (en) * | 2021-04-07 | 2021-07-20 | 赛克赛斯生物科技股份有限公司 | Preparation method of absorbable hemostatic fluid gelatin and absorbable hemostatic fluid gelatin |
-
2022
- 2022-01-19 CN CN202210061755.7A patent/CN114470302A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1615160A (en) * | 2001-12-21 | 2005-05-11 | 弗劳森公司 | A haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
| GB0410383D0 (en) * | 2004-05-10 | 2004-06-16 | Johnson & Johnson Medical Ltd | Absorbable haemostatic materials |
| US20110045034A1 (en) * | 2008-03-03 | 2011-02-24 | Israel Nur | Gelatin Sponge Comprising an Active Ingredient, Its Preparation and Use |
| CN103037847A (en) * | 2010-06-01 | 2013-04-10 | 巴克斯特国际公司 | Process for making dry and stable hemostatic compositions |
| CN108530671A (en) * | 2018-02-11 | 2018-09-14 | 广州迈普再生医学科技股份有限公司 | A kind of porous gelfoam and preparation method thereof |
| US20190343981A1 (en) * | 2018-05-09 | 2019-11-14 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
| CN109821059A (en) * | 2019-04-16 | 2019-05-31 | 大连医科大学附属第一医院 | A kind of preparation method of absorbable fluid gelatin hemostatic material |
| CN113134113A (en) * | 2021-04-07 | 2021-07-20 | 赛克赛斯生物科技股份有限公司 | Preparation method of absorbable hemostatic fluid gelatin and absorbable hemostatic fluid gelatin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11246938B2 (en) | Hemostatic microspheres | |
| Seyednejad et al. | Topical haemostatic agents | |
| Lubarsky et al. | Embolization agents—which one should be used when? Part 2: small-vessel embolization | |
| US9005609B2 (en) | Hemostatic compositions containing sterile thrombin | |
| US20210154351A1 (en) | Psyllium based moisture absorbent material | |
| US6059766A (en) | Gynecologic embolotherapy methods | |
| US20030148994A1 (en) | Hemostatic composition | |
| HU179969B (en) | Process for preparing an absorbable hemostatic composition | |
| Suwanprateeb et al. | Preparation and characterization of PEG–PPG–PEG copolymer/pregelatinized starch blends for use as resorbable bone hemostatic wax | |
| Clapp et al. | Small bowel obstruction after FloSeal use | |
| US2642375A (en) | Hemostatic compositions | |
| Adler et al. | “Macro” aneurysm in renal angiomyolipoma: two cases, with therapeutic embolization in one patient | |
| CN114470302A (en) | Hemostatic gel and preparation method thereof | |
| CN100453125C (en) | Non-viscous medical use liquid embolic agent | |
| JP6461957B2 (en) | Dry pad containing thrombin and pectin | |
| Anderson et al. | Placenta percreta complications | |
| JPH0794583B2 (en) | High water content polymer gel | |
| Cullifer et al. | Topical hemostatic and tissue-sealing agents in gynecologic surgery | |
| Wang et al. | Tuning Blood–Material Interactions to Generate Versatile Hemostatic Powders and Gels | |
| JP2007501688A6 (en) | Improved system and method for promoting hemostasis using absorbent sponges | |
| Dhulkotia et al. | Tisseel for management of traumatic postpartum haemorrhage | |
| Pandit et al. | Massive haemoperitoneum from a ruptured corpus luteal cyst | |
| Lucatelli et al. | Embolic Agents in Interventional Radiology in Gynecological and Obstetric Diseases | |
| CN210992034U (en) | Absorbable bone wax | |
| Qi et al. | Recent Progress on Water-based Liquid Embolic Agents in Endovascular Treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |